On the HCPLive Internal Medicine condition center page, resources on the topics of medical news and expert insight into internal medicine can be found. Content includes articles, interviews, videos, podcasts, and breaking news on internal medicine research, treatment, and drug development.
February 4th 2023
The sBLA for lanadelumab permits its use as a prophylaxis in children as young as 2 years old with the rare condition.
February 3rd 2023
January 28th 2023
An analysis of 2 decades worth of data from the Clinical Practice Research Datalink suggests all-cause mortality rates in type 2 diabetes have decreased but sheds light on upward trends in mortality from multiple different forms of cancer, including pancreatic, liver, and lung cancer, particularly among older patients.
A new study from clinicians in the VA Boston Healthcare System provides an overview of the impact the COVID-19 pandemic has had on racial disparities in wait times for new cardiology and orthopedic specialist consultations.
Using data from more than 500 patients with more than 6 years of follow-up suggests total caloric intake may be more effective for reducing weight loss than increasing the time between meals.
New data show patients who receive referred specialist care from a physician who went to medical school or other certification programs with their primary provider report better survey scores.
Promising results from the IMerge phase 3 clinical trial met the primary and secondary endpoints in the investigation of imetelstat, a novel telomerase inhibitor developed for hematologic malignancies.
Jesse Morse, MD, a sports medicine specialist, discusses commotio cordis and how to effectively communicate with athletes and parents of young athletes about the diagnosis in the wake of an incident where a player collapsed during a recent NFL game.
With a great deal of marginalized patients navigating burdensome, chronic, heterogenetic disease today, rheumatologists are becoming more invested in what the individual needs and wants from care.
As the treatment paradigm for neurologic diseases rapidly progresses, the need for more thorough biomarker tools to measure disease progression and severity has increased. In recent years, GFAP has emerged as a valuable candidate to add to the existing panel.
Despite its frequent use as a rescue therapy for patients with interstitial lung disease associated with connective tissue disorder, the effectiveness of rituximab hasn't been evaluated in many clinical trials.